Connect with us

PR Newswire

Snyk Builds Security into AWS CodePipeline to Mitigate Open Source Risk for Developer and Security Teams

Published

on

BOSTON, June 8, 2021 /PRNewswire/ — Snyk today announced it has built an integration inside the AWS CodePipeline console. This new integration allows AWS CodePipeline users to build automated security controls into their deployment pipeline without having to leave the Amazon Web Services (AWS) console, bringing the Snyk experience directly to AWS users, and empowering them to more efficiently find and fix vulnerabilities in open source code when building cloud native applications on AWS.

As security becomes an increasingly crucial priority for development teams, Snyk has worked closely with AWS to automate security tooling onto AWS’s continuous delivery services, accelerating triaging and empowering agility in development when making application and infrastructure updates.

Snyk’s integration inside the AWS CodePipeline console is the latest in a number of key integrations with AWS services, helping customers build security into applications at each level of the technology stack using an intuitive, developer-friendly security platform. Snyk allows DevOps and engineering teams to accelerate security testing by first detecting vulnerabilities in the developer IDE. Using Snyk’s feature-rich CLI, developers can also secure various elements of their workflow such as AWS CodeBuild and AWS CodeCommit. AWS users can then leverage Snyk’s integrations with Amazon Elastic Container Registry (Amazon ECR) and Amazon Elastic Kubernetes Service (Amazon EKS) to scan container images and Kubernetes clusters for vulnerabilities and misconfigurations, even mapping new vulnerabilities to any container images already deployed in a Kubernetes cluster. For serverless workloads, Snyk scans AWS Lambda functions for vulnerabilities and can gate deployments through the CI/CD stage to ensure that only secure workloads are permitted to run in production.

This latest integration inside the AWS CodePipeline console expands upon Snyk’s ongoing collaboration with AWS to ensure that both development and security teams are able to leverage automated tooling to mitigate their open source risk as part of the development process, positively affecting the way they work and interact with one another.

  • Development teams: can easily find, prioritize and fix vulnerabilities in their open source dependencies, delivering secure code faster than their competition without having to adopt gated security audits that disrupt application deployment.
  • Security teams: can enable improvements to the development process that ensure that all applications are continuously scanned for vulnerabilities without requiring the security team to manually meet the break-neck speed of modern application development.

“Snyk and AWS share a common goal: to facilitate a digital transformation for our customers through cloud native services that empower automation and developer engagement,” said Carey Stanton, VP of Business Development, Snyk. “Automation in deployment pipelines is key to adopting a comprehensive approach to security throughout the application development lifecycle. Snyk’s tight interoperability with AWS CodePipeline now makes it even simpler for developers to focus on building applications securely, taking advantage of developer-friendly outputs without having to manage a new set of tools.”

“AWS wants to empower our customers to focus their time and resources on innovating their business, which is why we collaborate with security leaders like Snyk to help automate manual security tasks in development,” said Ken Exner, Director, Developer Tools, AWS. “We’re delighted to be working with Snyk to allow our customers to be more agile when delivering secure applications to market.”

“As a hyper growth business, we need a security partner that can dynamically adapt to our needs and allow us to scale our security posture fast,” said Chaim Mazal, VP of Global Information Security, ActiveCampaign. “With Snyk’s developer first ethos and comprehensive Cloud Native Application Security platform, we’re continuously increasing visibility, mitigating risk, all while positioning our organization to achieve ambitious goals for developer productivity and innovation through our secure software development lifecycle.”

As an AWS Partner within the AWS Partner Network (APN), Snyk has been technically validated to work seamlessly with several AWS services, and has achieved AWS DevOps Competency as well as the AWS Lambda Ready and Amazon Linux 2 Ready designations.

Snyk has also recently announced the availability of Snyk Cloud Native Appliance (Snyk CNA), a self-hosted, dedicated instance of Snyk that can be deployed directly onto a customer’s private AWS environment, or even onto an AWS GovCloud environment, operating workloads up to Impact Level (IL) 5.

About Snyk

Snyk, a cloud native application security leader, today enables 2.2 million developers to build securely, with a vision to empower every modern developer in the world to develop fast and stay secure. Only Snyk provides a platform to secure all of the critical components of today’s cloud native application development including the code, open source libraries, container infrastructure, and infrastructure as code. Snyk’s developer-first approach enables technology-driven companies to scale security in today’s fast-paced digitally transforming world. Snyk’s security platform is powered by its industry-leading proprietary vulnerability database, maintained by the expert Snyk security research team, that also powers security solutions from strategic partners such as Atlassian, Datadog, Docker, IBM Cloud, Rapid7, Red Hat, and Trend Micro. The company works with global customers of all sizes to empower developers to automatically integrate security throughout their existing workflows.

Named to the 2020 Forbes Cloud 100, the definitive ranking of the top 100 private cloud companies in the world, Snyk was also recently recognized by Comparably as the #3 small-to-medium businesses for Happiest Employees in 2020.

For more information and to get started with Snyk for free today, visit https://snyk.io

SOURCE Snyk

Related Links

https://snyk.io

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/snyk-builds-security-into-aws-codepipeline-to-mitigate-open-source-risk-for-developer-and-security-teams-301307326.html

PR Newswire

Perfect World to pioneer digital culture and creative sector in joint hands with partners

Published

on

As a world’s leading entertainment group, Perfect World proposed “Creative Thinking” strategy, aiming at breaking the barrier of the real world and virtual world, and combining new types of games with traditional industries so as to empower the development of traditional industries and promote digital upgrade of traditional industries as well.

Under the “Creative Thinking” strategy, Perfect World has made significant achievements in its cooperation with enterprises and institutions, such as implanting scenes of the Qinhuai Lantern Fair of Nanjing Confucius Temple into its famous game “Zhuxian,” and the collaboration between its mobile game Chronicle of Infinity and the famous sports brand Peak.

Perfect World CEO Dr. Robert H. Xiao said at the conference that after all the successful cases, Perfect World has been more confident about cross-over cooperation between digital culture industry and traditional industries. He promised that Perfect World will keep exploring to establish a value chain that empowers traditional industries, and incubate more new types of culture content, products, and business models.

In its collaboration with Nianhuawan scenic spot in Wuxi, Perfect World gamified the scenic spots, and brought tourists an immersive experience by combing the scenic spot and the digital world. The move helps the scenic spot to upgrade from service-based economic to experience economy.

“Not only will we explore subdivided fields with partners, but also work as a bridge to promote cross-over cooperation among companies in various fields, so as to achieve common development,” said Dr. Xiao. “And we hope to joint hands with our partners to unlock a new track in this ‘experimental production’ of the culture industry that faces the future,” he added.

Perfect World will tailor a whole set of solutions and plans on digital upgrading partners’ products based on their requirements. For example, in its cooperation with Shanghai Science and Technology Museum, Perfect World will develop a game to turn the complicated scientific knowledge into visions to help readers understand the scientific knowledge. The Group will also have an in-depth cooperation with China Audio-video and Digital Publishing Association in the field of education and vocational training such as e-sports talent cultivation.

The culture department of Beijing’s Dongcheng district, People’s Cultural Tourism of People’s Daily, a cultural & creative institute affiliated to Tsinghua University, Beijing Dongsheng Bozhan Cloud Computing Technology Co., Ltd., and Nianhuawan scenic spot, also signed strategic cooperation agreements with Perfect World in the brand cooperation conference.

SOURCE Perfect World

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/perfect-world-to-pioneer-digital-culture-and-creative-sector-in-joint-hands-with-partners-301311222.html

Continue Reading

PR Newswire

European Hematology Association : la réponse humorale au vaccin Pfizer/BioNTech BNT162b2 est altérée chez les patients recevant un CAR-T ou un traitement immunosuppresseur de haute intensité

Published

on

LA HAYE, Pays-Bas, 12 juin 2021 /PRNewswire/ — Le vaccin Pfizer/BioNTech BNT162b2 a été approuvé pour la prévention de l’infection par le coronavirus 2 du syndrome respiratoire aigu sévère (SRAS-CoV-2) et est recommandé pour les patients immunodéprimés. Cependant, son efficacité et son innocuité chez les patients suivant une thérapie cellulaire immunologique n’ont pas été bien documentées. Dans le cadre de cette étude, nous avons évalué l’efficacité et l’innocuité du vaccin BNT162b2 chez les patients ayant subi une greffe de cellules hématopoïétiques (HCT) et un traitement au récepteur d’antigène chimérique (CAR)-T. Nous avons suivi prospectivement 79 patients vaccinés ayant été activement traités au Centre médical Sourasky de Tel Aviv et surveillé le profil d’innocuité et la réponse immunitaire humorale au vaccin.

Dans l’ensemble, le vaccin a été bien toléré et tous les effets indésirables se sont résorbés en quelques jours, à l’exception d’un rejet de greffe secondaire, qui fait toujours l’objet d’une enquête. Nous avons observé que seulement 36 % des patients ayant reçu un traitement CAR-T ont développé une réponse aux anticorps humoraux comparativement à 81 % des patients ayant subi une TSS allogénique. De plus, les patients atteints d’aplasie des cellules B et ceux ayant reçu le vaccin peu après la perfusion de cellules étaient moins susceptibles de développer des anticorps. Prises ensemble, ces données démontrent que la réponse humorale au vaccin BNT162b2 est significativement altérée chez les patients recevant le CAR-T, par opposition à ceux ayant reçu une TSS allogénique ayant une bonne réponse.

Présentateur : Professeur Ron Ram

Affiliation : Unité BMT, Tel Aviv Sourasky Medical Center, Tel Aviv, Israël

Résumé : #S285 INNOCUITÉ ET EFFICACITÉ DU VACCIN BNT162B2 MRNA COVID-19 CHEZ LES PATIENTS APRÈS UNE THÉRAPIE ALLOGÉNIQUE À BASE DE HCT ET DE CD19 – ÉTUDE DE COHORTE PROSPECTIVE À UN SEUL CENTRE

À propos du congrès annuel de l’AEH : Chaque année, en juin, l’AEH organise son congrès annuel dans une grande ville européenne. Cette année, en raison de la persistance de la pandémie de COVID-19, l’AEH organise pour la deuxième fois un Congrès virtuel. Le Congrès s’adresse aux professionnels de santé travaillant dans le domaine de l’hématologie ou s’y intéressant. Les sujets du programme scientifique vont de la physiologie et du développement des cellules souches à la leucémie, le lymphome, le diagnostic et le traitement, les globules rouges, les globules blancs et les troubles plaquettaires, l’hémophilie et le myélome, la thrombose et les troubles de la coagulation ainsi que la transfusion et la transplantation de cellules souches.

Site web :www.ehaweb.org

Logo – https://mma.prnewswire.com/media/622259/EHA_Logo.jpg

SOURCE European Hematology Association (EHA)

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/european-hematology-association-la-reponse-humorale-au-vaccin-pfizer-biontech-bnt162b2-est-alteree-chez-les-patients-recevant-un-car-t-ou-un-traitement-immunosuppresseur-de-haute-intensite-862309567.html

Continue Reading

PR Newswire

EHA:Eficacia de la vacuna Pfizer/BioNTech BNT162b2 en pacientes que reciben CAR-T

Published

on

– European Hematology Association:La respuesta humoral a la vacuna Pfizer/BioNTech BNT162b2 se ve afectada en pacientes que reciben CAR-T o terapia inmunosupresora de alta intensidad

LA HAYA, Países Bajos, 12 de junio de 2021 /PRNewswire/ — La vacuna Pfizer/BioNTech BNT162b2 ha sido aprobada para la prevención del síndrome respiratorio agudo severo por coronavirus 2 (SARS-CoV-2) y se recomienda para pacientes inmunosuprimidos. Sin embargo, su eficacia y seguridad en pacientes sometidos a terapia celular inmunológica no han sido bien documentadas. En este estudio, evaluamos la eficacia y seguridad de la vacuna BNT162b2 en pacientes que se sometieron a trasplante de células hematopoyéticas (HCT) y terapia con receptor de antígeno quimérico (CAR) -T. Seguimos prospectivamente a 79 pacientes vacunados que fueron tratados activamente en el Centro Médico Sourasky de Tel Aviv y monitoreamos el perfil de seguridad y la respuesta inmune humoral a la vacuna.

En general, la vacuna fue bien tolerada y todos los efectos secundarios se resolvieron en unos pocos días, excepto un rechazo secundario del injerto, que aún está bajo investigación. Observamos que solo el 36% de los pacientes que recibieron terapia CAR-T desarrollaron una respuesta humoral de anticuerpos en comparación con el 81% de los pacientes que se sometieron a un HCT alogénico. Además, los pacientes con aplasia de células B y los que recibieron la vacuna poco después de la infusión de células tenían menos probabilidades de desarrollar anticuerpos. Tomados en conjunto, estos datos demuestran que la respuesta humoral a la vacuna BNT162b2 está significativamente alterada en los pacientes que reciben CAR-T, a diferencia de aquellos después de un HCT alogénico que tuvieron una buena respuesta.

Presentador:  Profesor Ron Ram

Afiliación:  BMT Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Abstract: #S285  SAFETY AND EFFICACY OF THE BNT162B2 MRNA COVID-19 VACCINE IN PATIENTS AFTER ALLOGENEIC HCT AND CD19-BASED CAR-T THERAPY – A SINGLE CENTER PROSPECTIVE COHORT STUDY

Acerca del Congreso anual de EHA: Cada junio, la EHA organiza su Congreso Anual en una de las principales ciudades europeas. Este año, debido a la persistente pandemia de COVID19, EHA organiza un Congreso virtual por segunda vez. El Congreso está dirigido a profesionales de la salud que trabajen o estén interesados en el campo de la hematología. Los temas del programa científico van desde la fisiología y el desarrollo de las células madre hasta la leucemia; linfoma diagnostico y tratamiento; las células rojas de la sangre; trastornos de los glóbulos blancos y las plaquetas; hemofilia y mieloma; trombosis y trastornos hemorrágicos; así como transfusión y trasplante de células madre.

Sitio web: www.ehaweb.org

Logo – https://mma.prnewswire.com/media/622259/EHA_Logo.jpg

SOURCE European Hematology Association (EHA)

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/eha-eficacia-de-la-vacuna-pfizer-biontech-bnt162b2-en-pacientes-que-reciben-car-t-868759422.html

Continue Reading

PR Newswire

European Hematology Association: Overall Survival Benefit Established With Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) in Elderly Patients with Transplant-ineligible Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Interim Analysis of the MAIA Study

Published

on

THE HAGUE, Netherlands, June 12, 2021 /PRNewswire/ — The phase 3 MAIA study evaluated D-Rd versus Rd in 737 patients who were ineligible for high-dose chemotherapy and autologous stem cell transplantation. The primary analysis of MAIA demonstrated a 44% reduction in the risk of disease progression or death after treatment with D-Rd compared with Rd alone. At a median follow-up of almost 5 years (56.2 months), we now report the pre-specified interim overall survival analysis of MAIA.

The addition of daratumumab to Rd treatment significantly reduced the risk of death by 32% (hazard ratio, 0.68; 95% confidence interval [CI], 0.53-0.86; P=0.0013) with an estimated 5-year overall survival rate of 66.3% in the D-Rd group compared with 53.1% in the Rd alone group. These results are despite 46% of patients who received subsequent therapy in the Rd arm receiving daratumumab. Similarly, the significant progression-free survival benefit of D-Rd versus Rd that was identified in the primary analysis was maintained, with a 47% reduction in the risk of disease progression or death (HR, 0.53; 95% CI, 0.43-0.66; P<0.0001) and an estimated 60-month progression-free survival rate of 52.5% versus 28.7%, respectively; these data provide a new PFS benchmark for patients with NDMM who are transplant ineligible. The high overall response rate (93% vs 82%) further demonstrated the added clinical benefit of D-Rd versus Rd alone. No new safety concerns were identified for D-Rd and the most common (>15%) grade 3/4 treatment-emergent adverse events for D-Rd and Rd were neutropenia (54% vs 37%), pneumonia (19% vs 11%), anemia (17% vs 22%), and lymphopenia (16% and 11%). In conclusion, the clinical benefit from the primary analysis of the MAIA study was maintained through 5 years of follow-up and the benefit of upfront D-Rd given to progression was confirmed with a significant OS improvement, further supporting the use of frontline daratumumab as a new standard of care for patients with transplant-ineligible NDMM.

The results of this study will be presented by Prof. Thierry Facon on Saturday, June 12.

Presenter: Professor Thierry Facon

Affiliation: University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France

Abstract: #LB1901 OVERALL SURVIVAL RESULTS WITH DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 MAIA STUDY

About the EHA Annual Congress: Every year in June, EHA organizes its Annual Congress in a major European city. This year due to the persisting COVID19 pandemic, EHA organized a Virtual Congress for the second time. The Congress is aimed at health professionals working in or interested in the field of hematology.

Website: www.ehaweb.org

Logo – http://mma.prnewswire.com/media/622259/EHA_Logo.jpg

SOURCE European Hematology Association (EHA)

Related Links

https://ehaweb.org/

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.prnewswire.com:443/news-releases/european-hematology-association-overall-survival-benefit-established-with-daratumumab-plus-lenalidomide-and-dexamethasone-d-rd-in-elderly-patients-with-transplant-ineligible-newly-diagnosed-multiple-myeloma-ndmm-long-term-in-301310175.html

Continue Reading
Esports3 days ago

Genshin Impact Echoing Conch Locations Guide

Esports5 days ago

All 17 character locations in Collections in Fortnite Chapter 2, season 7

Esports4 days ago

Here are all the milestones in Fortnite Chapter 2, season 7

Blockchain5 days ago

BPI No Longer Allows Crypto Transactions

AR/VR5 days ago

‘Warhammer Age of Sigmar: Tempestfall’ Gets First Look at Gameplay, Invite-only Beta

Blockchain4 days ago

Doge meme Shiba Inu dog to be auctioned off as NFT

Esports4 days ago

What Time Does Minecraft 1.17 Release?

Esports4 days ago

How to Fly UFOs in Fortnite

Esports3 days ago

MLB The Show 21 Kitchen Sink 2 Pack: Base Round Revealed

Blockchain4 days ago

World Economic Forum Releases a DeFi Policy Toolkit for Fair and Executable Regulations

Esports5 days ago

How to unlock the Superman Skin in Fortnite Chapter 2, season 7

Blockchain5 days ago

Donald Trump on Bitcoin: “Essentially It’s a Currency Competing Against the Dollar”

Esports5 days ago

How to get Rick from Rick and Morty in Fortnite Chapter 2, season 7

zephyrnet3 days ago

7th Global Blockchain Congress by Agora Group & TDeFi on June 21st and 22nd, 2021, Dubai.

Aviation3 days ago

The Story Of The Boeing 777 Family

Gaming4 days ago

MUCK: How To Get The Best Weapon | Wyvern Dagger Guide

Blockchain3 days ago

Woonkly will be the official Title Sponsor of the 7th edition Global Blockchain Congress organized by Agora Group in Dubai

Crowdfunding5 days ago

US Government Claws Back Crypto from Ransomware Scam as Feds Flex Growing Tech Muscle

Blockchain3 days ago

Death Cross is Appearing Over Bitcoin Price Chart

Cyber Security5 days ago

How to Learn Cybersecurity On Your Own

Trending